Status: Recruiting
An Exploratory Clinical Study on the Safety and Efficacy of Anti-CD19/BCMA U CAR-T Cells in the Treatment of Relapsed/Refractory Immune-mediated Kidney Disease
A single arm, open-label pilot study is designed to determine the safety and effectiveness of anti-CD19/BCMA U CAR T cell injection (KN3601) in patients with Relapsed/Refractory immune-mediated kidney disease
Participants needed: 36
Trial details
Phase: Early Phase 1Age: 18-70Biological sex: AllType: InterventionalSponsor: Changhai HospitalUpdated: Feb 6, 2026Locations: 1
Eligibility criteria
Age: ≥ 18 years old and ≤ 70 years old, male or female; [+20]
Subjects known to have allergic reactions, hypersensitivity, intolerance, or con... [+17]